Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

计划入组 20 人 · 首次发布于 2022 年 9 月 1 日

Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation

计划入组 61 人 · 首次发布于 2021 年 6 月 23 日

Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

计划入组 516 人 · 首次发布于 2020 年 11 月 30 日

Abemaciclib(Verzenio, Verzenios)

C₂₇H₃₂F₂N₈ · Rx

HER2+ Breast Cancer(Diakonos)

oncology program (HER2+ breast cancer)

JAPAN BREAST CANCER RESEARCH GROUP

Japan

ANZ BREAST CANCER TRIALS GROUP LIMITED

Australia

International Breast Cancer Research Foundation

United States

FDA Grants Priority Review for Trodelvy in HR+/HER2- Metastatic Breast Cancer Following Positive Survival Data

Gilead's Trodelvy Fails Primary Endpoint in First-Line HR+/HER2- Metastatic Breast Cancer Trial

BRACELET-1 Trial Shows Promise for Oncolytic Virus Pelareorep in HR+ Breast Cancer